TY - JOUR
TI - IMMUNOLOCALIZATION OF TRANSITIONAL-CELL CARCINOMA OF THE BLADDER WITH
INTRAVESICALLY ADMINISTERED TC-99M LABELED HMFG1 MONOCLONAL-ANTIBODY
AU - MALAMITSI, J
AU - ZORZOS, J
AU - VARVARIGOU, AD
AU - ARCHIMANDRITIS, S and
AU - DASSIOU, C
AU - SKARLOS, DV
AU - DIMITRIOU, P
AU - LIKOURINAS, M
AU - ZIZI,
AU - A
AU - PROUKAKIS, C
JO - European Journal of Nuclear Medicine and Molecular Imaging
PY - 1995
VL - 22
TODO - 1
SP - 25-31
PB - Springer-Verlag
SN - 1619-7070, 1619-7089
TODO - 10.1007/BF00997244
TODO - TRANSITIONAL CELL CARCINOMA OF THE BLADDER; HMFG1 MONOCLONAL ANTIBODY;
INTRAVESICAL ADMINISTRATION; IMMUNOLOCALIZATION
TODO - The aim of this study was the immunolocalization of transitional cell
carcinoma of the bladder with a radiolabelled murine tumour-associated
monoclonal antibody and the measurement of the absolute uptake of the
antibody by the tumour. Fourteen patients with transitional cell
carcinoma of the bladder received 3-6 mCi (111-222 MBq) of
technetium-99m labelled HMFG1 monoclonal antibody intravesically and one
patient, 2 mCi (74 MBq) of iodine-131 labelled 11.4.1, which is a
non-tumour-specific monoclonal antibody. Four of the 15 patients were
evaluated with single-photon emission tomography (SPET) 1 1/2 to 2 h
post administration. All patients underwent transurethral resection of
the bladder tumour within 12-20 h following intravesical administration
of the radiolabelled antibody. The radioactivity of biopsy specimens
from normal urothelium and tumour areas were counted in a gamma counter.
The mean uptake of the radiolabelled antibodies from normal and tumour
sites was expressed as a percentage of the administered dose per
kilogram of tissue. Conventional histology and immunohistochemistry
using HMFG1 monoclonal antibody were performed on paraffin sections of
the biopsy specimens. Although our results are preliminary, it can be
concluded that: (a) bladder tumours are well imaged by SPET when using
Tc-99m-HMFG1; (b) intravesically administered radiolabelled antibody
remains on the bladder tissue and does not escape into the systemic
circulation; (c) the wide range of tumour uptake values (0%-9.3%
administered dose/kg) observed probably ran hp attributed to
heterogeneity of the antigenic expression of the tumour; (d) values of
Tc-99m-HMFG1 monoclonal antibody uptake by the tumour do not justify
future attempts at radioimmunotherapy.
ER -